April 3rd 2025
Researchers reported the case of a 28-year-old woman with epidermodysplasia verruciformis who developed SCC on a sun-protected scalp.
Clinical Consultations™: Optimizing Treatment Outcomes for Patients with Generalized Pustular Psoriasis
View More
Revolutionizing Atopic Dermatitis (RAD) Conference 2025
June 6-7, 2025
Register Now!
Cases and Conversations™: Biologic Matchmaking in Psoriasis – Finding the Right Therapy for the Right Patient
July 26, 2025
Register Now!
Advances in™ Atopic Dermatitis: Addressing Unmet Needs in Patients With Skin of Color
View More
Clinical Consultations™: Guiding Patients with Genital Psoriasis Toward Relief Through a Multidisciplinary Approach
View More
Patient, Provider & Caregiver Connection™: Understanding the Patient Journey to Provide Personalized Care for Generalized Pustular Psoriasis
View More
Cases and Conversations™: Applying Practice Techniques to Optimize Diagnosis and Treatment Strategies in Generalized Pustular Psoriasis
View More
Cases and Conversations™: Applying Best Practices to Prevent Shingles in Your Practice
View More
‘REEL’ Time Patient Counseling™: Fostering Effective Conversations in Practice to Create a Visible Impact for Patients Living with Genital Psoriasis
View More
Dermalorian™ Webinar: Shedding Light on Patient-Reported Outcomes to Assess Disease Severity in Patients With Atopic Dermatitis
View More
Where Do Biologics Fit Into the Management of Moderate-to-Severe Atopic Dermatitis?
View More
Expert Illustrations & Commentaries™: Exploring Novel Therapeutic Targets in Acne Management
View More
Burst CME: Targeted Therapy for Optimal Psoriasis Management
View More
Rising skin cancer rate spurs drive for new therapies
February 1st 2014The commercialization of ingenol mebutate (Picato, LEO Pharma) a medication that is currently approved in the United States and many other countries for the treatment of actinic keratosis, is an example of how enthusiasm and commitment can drive innovation, a LEO Pharma general manager says.
Questionnaires measure quality-of-life impact of carcinomas
January 21st 2014In an effort to learn more about patients’ experiences with advanced basal cell carcinoma and basal cell carcinoma nevus syndrome, researchers have developed two new questionnaires to evaluate and assess the effects of the diseases.
SCC staging update defines high-risk tumors
January 1st 2014A new tumor staging system for cutaneous squamous cell carcinoma (CSCC) has recently been put forward that, according to one recent study, improves prognostic discrimination by more precisely defining the small subset of tumors with a high risk of metastatic and death.
Initial accurate diagnosis critical for rare tumors
January 1st 2014Atypical fibroxanthoma (AFX) and undifferentiated pleomorphic sarcoma (UPS) share a similar histological picture. But unlike AFX, UPS can have an aggressive clinical course, underscoring the importance of initial accurate diagnosis of these tumors, and the implementation of appropriate therapy.
Body’s circadian rhythms affect skin stem cell regulation
October 22nd 2013New research suggests that the body’s internal clock and its circadian rhythms adjust the modulation of skin stem cells based on the time of day - and that disruption to this cycle can cause tissue aging and lead to predisposition to skin cancer.
AAD work groups aim to facilitate research within the specialty
September 1st 2013The American Academy of Dermatology (AAD) Council on Science and Research’s Research Agenda work group has identified three keys areas - pruritus, cutaneous oncology and performance measurement and outcomes - to target in the future for continuing research in the dermatology specialty.